These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20123556)

  • 41. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
    Meissner W; Hill MP; Tison F; Gross CE; Bezard E
    Trends Pharmacol Sci; 2004 May; 25(5):249-53. PubMed ID: 15120490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
    Streffer JR; Grachev ID; Fitzer-Attas C; Gomez-Mancilla B; Boroojerdi B; Bronzova J; Ostrowitzki S; Victor SJ; Fontoura P; Alexander R
    Mov Disord; 2012 Apr; 27(5):651-5. PubMed ID: 22508283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progress in neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2008 Apr; 15 Suppl 1():5-13. PubMed ID: 18353131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting mitochondria for neuroprotection in Parkinson's disease.
    Schapira AH
    Antioxid Redox Signal; 2012 May; 16(9):965-73. PubMed ID: 22229791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease.
    Carrera I; Cacabelos R
    Curr Neuropharmacol; 2019; 17(3):295-306. PubMed ID: 30479218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?
    Hung AY; Schwarzschild MA
    Curr Opin Neurol; 2007 Aug; 20(4):477-83. PubMed ID: 17620885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease.
    Doorn KJ; Lucassen PJ; Boddeke HW; Prins M; Berendse HW; Drukarch B; van Dam AM
    Prog Neurobiol; 2012 Aug; 98(2):222-38. PubMed ID: 22732265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parkinson's disease: genetics and pathogenesis.
    Shulman JM; De Jager PL; Feany MB
    Annu Rev Pathol; 2011; 6():193-222. PubMed ID: 21034221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trial designs used to study neuroprotective therapy in Parkinson's disease.
    Lang AE; Melamed E; Poewe W; Rascol O
    Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers for trials of neuroprotection in Parkinson's disease.
    Agarwal PA; Stoessl AJ
    Mov Disord; 2013 Jan; 28(1):71-85. PubMed ID: 22927101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances and challenges in the dosage form design for the treatment of Parkinson's disease.
    Wen MM
    Discov Med; 2012 Dec; 14(79):369-77. PubMed ID: 23272689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New hopes for disease modification in Parkinson's Disease.
    Poewe W; Seppi K; Marini K; Mahlknecht P
    Neuropharmacology; 2020 Jul; 171():108085. PubMed ID: 32298705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical biomarkers of Parkinson disease.
    Wu Y; Le W; Jankovic J
    Arch Neurol; 2011 Jan; 68(1):22-30. PubMed ID: 21220674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physical exercise and Parkinson's disease: influence on symptoms, disease course and prevention.
    Grazina R; Massano J
    Rev Neurosci; 2013; 24(2):139-52. PubMed ID: 23492553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological therapy in Parkinson's disease: focus on neuroprotection.
    Kincses ZT; Vecsei L
    CNS Neurosci Ther; 2011 Oct; 17(5):345-67. PubMed ID: 20438581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of Parkinson disease: what do we need to show neuroprotection?
    Ybot-Gorrin I; Vivancos-Matellano F; Chacón-Peña JR; Alonso-Navarro H; Jiménez-Jiménez FJ
    Neurologist; 2011 Nov; 17(6 Suppl 1):S21-9. PubMed ID: 22045322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo.
    Ceravolo R; Sgadò P; Frosini D; Corsini GU
    J Neural Transm Suppl; 2006; (71):133-41. PubMed ID: 17447424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroprotection in Parkinson's disease: myth or reality?
    Voss T; Ravina B
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):304-9. PubMed ID: 18590614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.